MR Spectroscopy (MRS) provides early biomarkers of brain injury and treatment response in neonates with hypoxic-ischemic encephalopathy. We present preliminary data from the High-dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) Trial (NCT02811263), comparing quality assurance parameters across MR vendors. Overall, we have been able to analyze MRS data obtained from 85% of patients who underwent MRI, although this rate is lower at sites operating GE MR systems. 92% of spectra met quality standards, with slight differences in FWHM and SNR by vendor. Overall, these data demonstrate the feasibility of obtaining reliable MRS data in a multicenter neonatal randomized controlled trial.